Page 1 | Search Results | Cancer Immunology Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Activation of CD8⁺ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Jessica L.F. Teh, Dan A. Erkes, Phil F. Cheng, Manoela Tiago, Nicole A. Wilski, Conroy O. Field, Inna Chervoneva, Mitch P. Levesque, Xiaowei Xu, Reinhard Dummer, Andrew E. Aplin

Cancer Immunol Res (2020) 8 (9): 1114–1121.

https://doi.org/10.1158/2326-6066.CIR-19-0743

Published: 01 September 2020

View articletitled, Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Includes: Supplementary data

Journal Articles

Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Emilio Sanseviero, Erin M. O’Brien, Jenna R. Karras, Tamer B. Shabaneh, Bulent Arman Aksoy, Wei Xu, Cathy Zheng, Xiangfan Yin, Xiaowei Xu, Giorgos C. Karakousis, Ravi K. Amaravadi, Brian Nam, Mary Jo Turk, Jeff Hammerbacher, Mark P. Rubinstein, Lynn M. Schuchter, Tara C. Mitchell, Qin Liu, Erica L. Stone

Cancer Immunol Res (2019) 7 (8): 1371–1380.

https://doi.org/10.1158/2326-6066.CIR-18-0386

Published: 01 August 2019

View articletitled, Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Includes: Supplementary data

Journal Articles

Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response

Cancer Immunol Res (2016) 4 (11_Supplement): PR05.

https://doi.org/10.1158/2326-6066.IMM2016-PR05

Published: 31 October 2016

View articletitled, Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response

Journal Articles

Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients

Cancer Immunol Res (2016) 4 (1_Supplement): A056.

https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A056

Published: 03 January 2016

View articletitled, Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients

Journal Articles

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

David L. Bajor, Rosemarie Mick, Matthew J. Riese, Richman P. Lee, Xiaowei Xu, Drew A. Torigian, Erietta Stelekati, Martha Sweeney, Brendan J. Sullivan, Lynn M. Schuchter, Ravi Amaravadi, E John Wherry, Robert H. Vonderheide

Cancer Immunol Res (2015) 3 (10_Supplement): A38.

https://doi.org/10.1158/2326-6074.TUMIMM14-A38

Published: 09 October 2015

View articletitled, Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

Journal Articles

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

David L. Bajor, Xiaowei Xu, Drew A. Torigian, Rosemarie Mick, Laura R. Garcia, Lee P. Richman, Cindy Desmarais, Katherine L. Nathanson, Lynn M. Schuchter, Michael Kalos, Robert H. Vonderheide

Cancer Immunol Res (2014) 2 (11): 1051–1058.

https://doi.org/10.1158/2326-6066.CIR-14-0154

Published: 02 November 2014

View articletitled, Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Activation of CD8⁺ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response

Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

Email alerts

AACR Journals

Update search

Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response

Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Activation of CD8⁺ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors